Skip to main content
Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc. — Investor Relations & Filings

Ticker · CRDF ISIN · US14147L1089 LEI · 549300AHOLZBHHYFWP04 US Professional, scientific and technical activities
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2025-02-27 Capital/Financing Update
Country US United States of America
Listing US CRDF

About Cardiff Oncology, Inc.

https://cardiffoncology.com/

Cardiff Oncology, Inc. is a clinical-stage biotechnology company developing novel cancer therapies. The company's primary focus is on leveraging the inhibition of Polo-like kinase 1 (PLK1), a well-validated oncology drug target. Its lead drug candidate, onvansertib, is an oral PLK1 inhibitor being evaluated in clinical trials. These programs test onvansertib in combination with standard-of-care therapeutics for various cancer indications. The company's strategy is designed to target tumor vulnerabilities to overcome treatment resistance and improve clinical outcomes for patients with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933 for the purpose of registering securities for sale, including common stock, preferred stock, debt securities, warrants, and units. The document includes a base prospectus and a sales agreement prospectus, describing the terms of securities offerings and the plan of distribution. It is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed registration and offering information, not just an announcement or notice, so it is not RPA or RNS. Confidence is high given the clear identification of the form and content.
2025-02-27 English
10-K
Annual Report FY 2024
2025-02-27 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-05 English
8-K
Governance Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The key content is the approval of Amended and Restated By-laws by the Board of Directors, which is a governance-related update. The document includes the filing of the amended by-laws as an exhibit. The length is 2867 characters, which is relatively short and the document is primarily an announcement of a governance change rather than the full text of the by-laws or a detailed governance report. Therefore, the best fitting category is 'Governance Information' (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. Confidence is high given the clear mention of amended by-laws and the nature of the filing.
2025-01-06 English
4
Director's Dealing
2024-12-18 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-12-17 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.